Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.
Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.
German biopharma company’s complaint against Palo Alto competitor prompts commission to investigate | Patents in dispute relate to bio-layer interferometry.
Conflict with name of patents for grapes and cherries prompts denial | If permitted, mark would “impede free use in the marketplace of a varietal denomination” following the patent’s expiration.
Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.
Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
Life sciences practice boosted by four-partner ‘powerhouse’ team | Attorneys have all achieved notable trial outcomes for pharma companies.
Jazz accused a rival of infringement | Avadel filed a counterclaim seeking to delist the patent from the Orange Book.
The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.
The complaint centres on profiling tech used in genetic analysis | Last year, 10x Genomics accused NanoString of infringing multiple patents related to spatial profiling.